Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IL2 CD25 fusion protein - Bristol-Myers Squibb

Next Previous
X
Search
Drug Profile

IL2 CD25 fusion protein - Bristol-Myers Squibb

Alternative Names: IL-2/CD25 - Bristol-Myers Squibb; IL2 CD25 - Bristol-Myers Squibb; Interleukin-2/interleukin-2 receptor alpha fusion protein - Bristol-Myers Squibb

Latest Information Update: 12 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Miami
  • Developer Bristol-Myers Squibb
  • Class Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 2 replacements; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 12 Jun 2024 IL2 CD25 fusion protein is still in phase I trial for Autoimmune-disorders in USA (Intraperitoneal, Injection) (Bristol-Myers Squibb pipeline, June 2024)
  • 19 Apr 2021 Bristol-Myers Squibb has patents pending worldwide for IL2 CD25 fusion protein and methods of use
  • 19 Apr 2021 University of Miami has patents pending worldwide for IL2 CD25 fusion protein and methods of use

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top